SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
US NAT yield: where are we after 2 years?
8 references·2 citing·35 second hop
US NAT yield: where are we after 2 years? (2002)US NAT yield: where are we after 2 years?Nucleic acid amplification testing of blood donors fortransfusion‐transmitted infectious diseases (2000)Nucleic acid amplification te…NAT of the United States and Canadian blood supply (2000)NAT of the United States and …NAT and blood safety: what is the paradigm? (2000)NAT and blood safety: what is…Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting (1999)Feasibility and efficacy of r…False-Positive HIV-1 Test Results in a Low-Risk Screening Setting of Voluntary Blood Donation (1998)False-Positive HIV-1 Test Res…The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection (1997)The incidence/window period m…The Risk of Transfusion-Transmitted Viral Infections (1996)The Risk of Transfusion-Trans…Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study (1995)Declining value of alanine am…HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas® TaqScreen MPX test in seroconverting donors (2007)HIV-1, HCV and HBV seronegati…Detection of an early HIV‐1 infection by HIV RNA testing in an Italian blood donor during the preseroconversion window period (2003)Detection of an early HIV‐1 i…Clinical Decision Analysis (1980)Donor Transaminase and Recipient Hepatitis (1981)EVALUATING THE COST-EFFECTIVENESS OF CLINICAL AND PUBLIC HEALTH MEASURES (1998)Handling uncertainty when performing economic evaluation of healthcare interventions. (1999)Preference-Based Measures in Economic Evaluation in Health Care (2000)Clinical decision analysis (2005)Collection and transfusion of blood and blood components in the United States, 1992 (1995)Collection and transfusion of blood and blood components in the United States, 1994 (1998)Failure of Routine HIV-1 Tests in a Case Involving Transmission With Preseroconversion Blood Components During the Infectious Window Period (2000)Results of Viral Marker Screening of Unpaid Blood Donations and Probability of Window Period Donations in 1997 (2000)The National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): Twenty Years of Research to Advance Blood Product Safety and Availability (2012)Transmission of Human Immunodeficiency Virus (HIV) by Blood Transfusions Screened as Negative for HIV Antibody (1988)Exposure of Patients to Human Immunodeficiency Virus through the Transfusion of Blood Components That Test Antibody-Negative (1989)Evaluation of Screened Blood Donations for Human Immunodeficiency Virus Type 1 Infection by Culture and DNA Amplification of Pooled Cells (1991)International application of the Incidence Rate/Window Period model (2002)Current incidence and estimated residual risk of transfusion‐transmitted infections in donations made to Canadian Blood Services (2007)Science and the Precautionary Principle (2000)Trends in Incidence and Prevalence of Major Transfusion-Transmissible Viral Infections in US Blood Donors, 1991 to 1996 (2000)Residual risk of transfusion‐transmitted HCV and HIV infections by antibody‐screened blood in Italy (2002)HIV Transmission Through Transfusion—Missouri and Colorado, 2008 (2011)Nucleic acid amplification technology methods used in blood donor screening (2002)Multicenter performance evaluation of a transcription‐mediated amplification assay for screening of human immunodeficiency virus‐1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations (2005)Blood donor screening with cobas s 201/cobas TaqScreen MPX under routine conditions at German Red Cross institutes (2009)Current prevalence and incidence of infectious disease markers and estimated window‐period risk in the American Red Cross blood donor population (2002)The value of increased neopterin levels in reducing transfusion-transmitted virus infections: detection of a donation from a HBsAg positive chronic carrier by screening of neopterin in Turkish blood donors (2005)Routine HIV screening among blood donors in Buenos Aires (Argentina): Results from six years’ experience and report of a single window-period donation (2007)Estimated Risk of Transmission of the Human Immunodeficiency Virus by Screened Blood in the United States (1995)Reducing the risk of infection from plasma products: specific preventative strategies (2000)International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009 (2011)Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States (2004)Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors. (2008)Yield of HCV and HIV‐1 NAT after screening of 3.6 million blood donations in central Europe (2002)First report of human immunodeficiency virus transmission via an RNA‐screened blood donation (2004)Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing (2004)A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors (2005)
this work references cited by second hop

References

  • 1996The Risk of Transfusion-Transmitted Viral Infections1,865 cited
  • 1999Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting254 cited
  • 2000Nucleic acid amplification testing of blood donors fortransfusion‐transmitted infectious diseases218 cited
  • 1997The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection168 cited
  • 2000NAT of the United States and Canadian blood supply142 cited
  • 1995Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study124 cited
  • 1998False-Positive HIV-1 Test Results in a Low-Risk Screening Setting of Voluntary Blood Donation122 cited
  • 2000NAT and blood safety: what is the paradigm?68 cited

Cited by

  • 2007HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas® TaqScreen MPX test in seroconverting donors23 cited
  • 2003Detection of an early HIV‐1 infection by HIV RNA testing in an Italian blood donor during the preseroconversion window period17 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work